Historical perspective on the treatment of essential thrombocythemia and polycythemia vera.
Since 1970, the treatment of essential thrombocythemia (ET) and polycythemia vera (PV) has evolved from alkylating agents to hydroxyurea (HU), and more recently to agents such as interferon-alpha (IFN) and anagrelide. While the earlier treatments for ET and PV have been successful in varying degrees, diagnosis of these disorders is being made earlier and in populations deemed at lower risk, but who may suffer greatly from the toxicity of long-term treatment with these agents. Thus, the risks and benefits of treatment versus nontreatment and between types of therapy have created a need for treatments that are safer for more people for greater lengths of time.